Earnings roundup: Gilead’s ‘uncertain’ future, Pfizer’s crossroads and Merck’s PCSK9 launch

EarningsPCSK9 inhibitorNegative

AI Analysis

Summary

Earnings roundup covering Gilead's uncertain future and drug launches, Pfizer's potential growth trajectory shift from an important trial readout, and Merck's PCSK9 inhibitor launch, with some analysts expressing concerns about execution risks.

Importance:5/10

Sentiment:

-0.30

earningsdrug_launchtrial_readoutPCSK9

Related Companies

$GILD $PFE $MRK

Read the original article

Published by BioPharma Dive on August 5, 2026 3:00 PM

Read Original